Figure 2. Pharmacokinetic-pharmacodynamic modeling of vecuronium. Fitted vecuronium's effect compartment concentration versus neuromuscular block. (A) Observed in the control group (n = 10). (B) Observed in the carbamazepine group (n = 10).
Figure 2. Pharmacokinetic-pharmacodynamic modeling of vecuronium. Fitted vecuronium's effect compartment concentration versus neuromuscular block. (A) Observed in the control group (n = 10). (B) Observed in the carbamazepine group (n = 10).
